Speeding up the translation from bench to bedside
Objective:
Improve the translational approach in research to increase the number of new treatments and prevention strategies that will become available in health care for OA patients.
Task 2.1: Technical and economic hurdles associated with the establishment and implementation of translational research models (crossing the Valley of Death).
Task 2.2: Guidelines for data collection, sampling, phenotyping, endotyping and clinical trial designs for companies bringing products targeting OA to the market to avoid common repeated failures in phase 2 and 3 clinical trials.
Task 2.3: Identification of the major challenges associated with translation from preclinical models to humans without intermediate translational models.
Task 2.4: European Consensus on Chronic Disease Self-Management Program CDSMP program for OA prevention.
Deliverables
On the 30th of January 2025, at 12pm CET, we had the WG2 Monthly Meeting, that took place online.
In this meeting we had an overview, and discussed the progress of the work being developed in our WG. We have currently one online survey and five manuscripts being prepared, covering different aspects of OA, from biomolecules and natural products used in disease management, to pre-clinical in vitro and in vivo models used for OA research, and also on surrogate outcomes and predictive markers for knee OA development. This month one of the manuscripts was registered as a systematic review and another one gave rise to an abstract, that has been submitted for presentation at a conference.
We also discussed future initiatives, like a webinar series, in terms of format, time-frame and focus.
Finally, we discussed the agenda for the face-to-face meeting that will take place in February in Brussels.